BofA cuts Public Service Enterprise stock price target on regulatory focus

BofA cut its price target on Public Service Enterprise Group to $85 from $87 but maintained a Buy rating; the shares were cited at $72.11. Investors are expected to focus on PSE&G’s upcoming base-rate filing and New Jersey regulatory review, alongside the outlook for nuclear earnings and power prices. In recent Q2 2026 results, non-GAAP operating EPS of $0.86 beat the $0.83 estimate, while revenue of $2.55 billion missed the $2.73 billion forecast; management reaffirmed full-year earnings guidance. The company’s dividend yield was reported at 3.72%.

Analysis

The key valuation variable is not simply whether New Jersey keeps investing, but how quickly PSE&G can convert capital spending into recoverable earnings under revised mechanisms. A filing that reduces reliance on trackers could improve visibility while also increasing exposure to timing lag and regulatory disallowance; the filing and review outcomes matter more than the analyst target changes. In the power segment, stronger capacity and energy pricing can lift the upside case, but basis volatility and the availability and economics of hedges determine how much reaches realized earnings. Bilateral nuclear contracts are a potential stabilizer, not bankable upside until counterparties, terms, and volumes are verifiable.

Near term, the earnings beat alongside a revenue miss and reaffirmed guidance argues against treating one quarter as a clean acceleration signal. Over 1–3 months, the year-end rate-case filing and New Jersey/PJM decisions are the catalysts; over 6–18 months, the structural question is whether rate-base growth translates into EPS without adverse recovery changes or weaker nuclear realizations. Consensus Buy ratings and optimistic target-based upside may underprice regulatory execution risk. Conversely, a process focused on recovery mechanics rather than the need for investment could limit downside if allowed returns and recovery timing remain workable. No independent evidence here establishes the likely ruling or the economics of prospective nuclear contracts.

Key Decisions for Investors

• Treat PEG as a catalyst-driven, moderate-conviction long rather than buying solely against sell-side targets. Consider adding only after the filing clarifies allowed recovery and timing; the thesis is weakened by a materially adverse regulatory outcome, reduced earnings guidance, or evidence that investment recovery lags spending.
• For the next 1–3 months, monitor the base-rate filing, New Jersey review milestones, and PJM capacity/basis developments. Verify filing details and realized power results against guidance before underwriting incremental earnings.
• Do not capitalize bilateral nuclear contracting as upside until contract counterparties, duration, volumes, and pricing are disclosed or otherwise independently verified. A failure to secure favorable terms would remove a potential offset to regulatory and basis risk.
• Avoid extrapolating the quarterly EPS beat into a stronger growth trajectory while revenue missed and guidance was reaffirmed. Reassess if subsequent results or guidance show deterioration in utility earnings or nuclear performance; BAC and HSBC are analyst institutions in this coverage, not direct beneficiaries of PEG's operating catalysts.